metricas
covid
Buscar en
Revista de Psiquiatría y Salud Mental (English Edition)
Toda la web
Inicio Revista de Psiquiatría y Salud Mental (English Edition) The comprehensive treatment of delusional disorder
Información de la revista
Vol. 10. Núm. 4.
Páginas 221-223 (octubre - diciembre 2017)
Vol. 10. Núm. 4.
Páginas 221-223 (octubre - diciembre 2017)
Letter to the Editor
Acceso a texto completo
The comprehensive treatment of delusional disorder
El tratamiento integral del trastorno delirante
Visitas
6189
José E. Muñoz-Negroa,
Autor para correspondencia
jemunoznegro@gmail.com

Corresponding author.
, Jorge A. Cervillaa,b
a UGC de Salud Mental, Complejo Hospitalario Universitario de Granada, Servicio Andaluz de Salud, Granada, Spain
b Departamento de Psiquiatría, Facultad de Medicina, Universidad de Granada, Granada, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo
Dear Editor,

The ethical principles which govern medical practice, in this case psychiatry, underline the need for patients to be treated as comprehensively as possible, as is demanded by the principles of care, dignity, integrity and justice.1 In spite of the fact that the prevalence of delusional disorder (DD) stands at 0.18% of the population2 there are no clinical practice guides (CPG) for DD which guide its treatment, so that the information from the schizophrenia CPG is used instead. This may be due to the fact that its place in psychiatric hospital care has not been clearly defined to date, as it has varied between being considered a schizophrenia subtype,3 an affective disorder4 or a separate entity.5 It is now defined in the CIE-106 as a psychosis involving persistent delirious ideas, although functioning is relatively well conserved, while there may also be a few other psychotic symptoms such as negative symptoms and minor hallucinations. Nevertheless, recent studies not only contribute to establishing this disorder as a differentiated entity,7–11 as they also rule out the possibility that it is a monosymptomatic disorder12 and emphasise the existence of different dimensions of the same, as well as its high comorbidity. Although the delirious symptom is not specific to DD, which therefore justifies its inclusion within the psychotic spectrum,13 it has been shown to have certain specific qualities and characteristics which differentiate it from schizophrenia. Thus while DD would display fewer delirious ideas than is the case in schizophrenia, they would be more intense. There would also be certain qualitative differences respecting schizophrenia. The predominance of somatic or jealous delirious ideas would be intrinsic to DD in comparison with those profiles which predominantly display religious delirious ideas that would be characteristic of schizophrenia.7 The other dimensions of DD underline not only the role of delirious ideas but also the relevant importance of affective symptoms, especially depression,8,9,13 cognitive symptoms9,13,14 or the risk of suicide as a comorbidity.15 Likewise, poorer awareness of the disease has also been detected, or even a worse response to antipsychotic drugs than is the case in schizophrenia.7 All of these factors mean that this disorder has its own peculiarities and profile which make it necessary treat it more widely than the delirious symptom alone or merely to extrapolate from data on schizophrenia treatments.

Pharmacological treatment is currently considered to be standard for the treatment of DD, and antipsychotic drugs are the cornerstone of this. A recent systemic review of descriptive studies which cover 385 DD patient cases treated using drugs16 has shown these to be effective, as there is a ≥50% improvement over the basal situation in 33.6% of cases, while first generation antipsychotics (FGA) are superior to second generation ones (SGA) (FGA 39% vs SGA 28%; χ2=5.2595; P.02; RR: 1.40; IC 95%: 1.04–1.88), while no specific individual antipsychotic is superior any other. More data are required on the latest antipsychotic drugs, given that the majority of the data on SGA refer to Risperidone or Olanzapine, while it would be of interest to determine the role of antipsychotic drugs which have an outstanding mood regulating function, as is the case for Quetiapine, or good tolerability such as Aripiprazol. Antidepressive drugs too may play a promising role in treatment, given the importance of the above-mentioned depressive dimension and other symptoms such as anxiety or irritability, as well as the good overall response to them which has been found. This is better than the response to antipsychotic drugs (response ≥50% in 50% of cases), although the sample size was small. They may be especially useful in the somatic subtype.16 Patient lack of awareness of the disease and possible lack of adherence also suggest a role for prolonged liberation parenteral drugs as well as the possible role of psychoeducation and psychological therapies aimed at improving the capacity for introspection, awareness of the disease and adherence. Cognitive-behavioural therapy has also been shown to have a moderate effect in improving secondary variables such as the social self-esteem of these patients.17 It would also be necessary to study the potential of treatments of this type or other psychological treatments such as metacognitive training on the cognitive traits underlying the delirious ideas which characterise DD, or cognitive repair18 of the cognitive symptoms existing in the disorder. To conclude, we emphasise that given that the intrinsic profile of the disorder is becoming increasingly consolidated, studies and especially clinical trials or large-scale naturalistic studies are necessary to study the treatment of DD as a differentiated entity rather than a schizophrenia sub-group under the heading of “other psychoses”.

Transparency declaration: the main author, José Eduardo Muñoz Negro, declares this manuscript to be an honest, accurate and transparent description of the study presented, that no important aspect of the study or studies described has been omitted, and that differences respecting the study initially planned have been explained (and if they are relevant, registered).19,20

References
[1]
F. Lolas-Stepke.
Tendencias y necesidad clínica de los principios éticos.
Rev Psiquiatr Salud Ment (Barc), 8 (2015), pp. 1-2
[2]
J. Perala, J. Suvisaari, S.I. Saarni, K. Kuoppasalmi, E. Isometsa, S. Pirkola, et al.
Lifetime prevalence of psychotic and bipolar I disorders in a general population.
Arch Gen Psychiatry, 64 (2007), pp. 19-28
[3]
E. Bleuler.
Dementia praecox oder Gruppe der Schizophrenien.
Handbuch der Psychiatrie,
[4]
D. Henderson, R. Gillespie.
A textbook of psychiatry for students and practitioners.
Oxford University Press, (1994),
[5]
E. Kraepelin.
Lehrbuch der Psychiatrie.
8th ed., Barth, (1909–1913),
[6]
WHO.
ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research 1993.
WHO, (1993),
[7]
V. Peralta, M.J. Cuesta.
Delusional disorder and schizophrenia: a comparative study across multiple domains.
Psychol Med, 46 (2016), pp. 2829-2839
[8]
A. Serretti, E. Lattuada, C. Cusin, E. Smeraldi.
Factor analysis of delusional disorder symptomatology.
Compr Psychiatry, 40 (1999), pp. 143-147
[9]
E. De Portugal, N. González, V. del Amo, J.M. Haro, C.M. Díaz-Caneja, J. de Dios Luna del Castillo, et al.
Empirical redefinition of delusional disorder and its phenomenology: the DELIREMP study.
Compr Psychiatry, 54 (2013), pp. 243-255
[10]
A. Marneros, F. Pillmann, T. Wustmann.
Delusional disorders – are they simply paranoid schizophrenia?.
Schizophr Bull, 38 (2012), pp. 561-568
[11]
J.E. Muñoz-Negro, I. Ibanez-Casas, E. de Portugal, V. Lozano-Gutiérrez, R. Martínez-Leal, J.A. Cervilla.
A psychopathological comparison between delusional disorder and schizophrenia.
Can J Psychiatry, (2017),
[in press]
[12]
J.E. Muñoz-Negro, V. Lozano, I. Ibanez-Casas, B.G. de la Cruz, A. Soler, J.A. Alcalá, et al.
Negative symptoms across psychotic spectrum disorders.
Eur J Psychiatry, 31 (2017), pp. 37-41
[13]
J.E. Muñoz-Negro, I. Ibanez-Casas, E. de Portugal, S. Ochoa, M. Dolz, J.M. Haro, et al.
A dimensional comparison between delusional disorder, schizophrenia and schizoaffective disorder.
Schizophr Res, 169 (2015), pp. 248-254
[14]
I. Ibanez-Casas, E. de Portugal, N. Gonzalez, K.A. McKenney, J.M. Haro, J. Usall, et al.
Deficits in executive and memory processes in delusional disorder: a case–control study.
[15]
A. González-Rodríguez, O. Molina-Andreu, V. Navarro Odriozola, C. Gastó Ferrer, R. Penadés, R. Catalán.
Suicidal ideation and suicidal behaviour in delusional disorder: a clinical overview.
Psychiatry J, 2014 (2014), pp. 834901
[16]
J.E. Muñoz-Negro, J.A. Cervilla.
A systematic review on the pharmacological treatment of delusional disorder.
J Clin Psychopharmacol, 36 (2016), pp. 684-690
[17]
M. Skelton, W.A. Khokhar, S.P. Thacker.
Treatments for delusional disorder.
Schizophr Bull, 41 (2015), pp. 1010-1012
[18]
A. González-Rodríguez, O. Molina-Andreu, R. Penadés, M. Bernardo, R. Catalán.
Therapeutic approach to delusional disorder based on psychopathological complexity: proposal for a decision model.
J Clin Psychopharmacol, 35 (2015), pp. 201-202
[19]
F. Catalá-López, D. Moher, R. Tabarés-Seisdedos.
Improving transparency of scientific reporting to increase value and reduce waste in mental health research.
Rev Psiquiatr Salud Ment (Barc), 9 (2016), pp. 1-3
[20]
F. Catalá-López, B. Hutton, M.J. Page, E. Vieta, R. Tabarés-Seisdedos, D. Moher.
Declaración de transparencia: un paso hacia la presentación completa de artículos de investigación.
Rev Psiquiatr Salud Ment (Barc), 9 (2016), pp. 63-64

Please cite this article as: Muñoz-Negro JE, Cervilla JA. El tratamiento integral del trastorno delirante. Rev Psiquiatr Salud Ment (Barc). 2017;10:221–223.

Copyright © 2017. SEP y SEPB
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos